News 2020
Click! Resistant bacteria caught in the act
22/06/2020

In a study published in Nature Chemical Biology, a team led by Jean-François Collet (WELBIO investigator at the UCLouvain, offers an unprecedented perspective on the defense mechanisms of bacteria, contributing to the global effort to respond to antibiotic resistance.


A better understanding of embryonic development
27/05/2020

In a study published in Nature, Isabelle Migeotte (WELBIO 2015-2019 - ULB) and her colleagues clarify a key stage of embryonic development. This data is essential for improving the production of synthetic embryos and limit the use of animal embryos.


Type 1 diabetes: how interferon-α impacts human pancreatic β-cells.
25/05/2020

In a recent paper published in Nature Communications, Decio L. Eizirik (WELBIO investigator at ULB) and colleagues used a multi-omics approach to clarify the impact of interferon-α on human beta cells.


Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure
20/05/2020

In a recent review paper published in Nature Reviews Endocrinology. Decio L. Eizirik (WELBIO investigator at ULB) and colleagues discuss the mechanisms leading to pancreatic beta cell failure in diabetes.


The balancing act of an allosteric magician: How ppGpp, the ‘magic spot’, controls its own fate
13/05/2020

The groups of Abel Garcia-Pino (WELBIO investigator at ULB) and his colleagues at the universities of Hasselt and Umeå, unravel the mysteries of the regulation of bacterial stringent response by the alarmones. Their study has been published in Nature Chemical Biology.


An anti-diabetes therapy for treating severe infections in a rare disease
02/05/2020

First patients suffering from a rare disease named Glycogen Storage Disease 1B have been successfully treated with an anti-diabetes therapy. This study is led by Maria Veiga-da-Cunha (senior research associate FRS-FNRS at UCLouvain) and Emile Van Schaftingen (WELBIO investigator at UCLouvain). The results have been published in Blood. For the first time in a WELBIO project, investigators make a successful step from basic research to actual patient treatment.


How ammonium transport induces yeast filamentation
28/04/2020

Anna Maria Marini (Welbio investigator and senior research associate at the Universite Libre de Bruxelles), and her co-workers describe the molecular mechanism by which yeast Mep2 transceptors induce filamentation as they transport ammonium through the cellular membrane. This study is published in PLoS Genetics.


Type 1 diabetes: a long non coding RNA regulates the pancreatic β-cell inflammation
26/04/2020

In a study published in PNAS, the teams of Decio E. Eizirik (WELBIO investigator at the Université libre de Bruxelles) and his former postdoctoral fellow Izortze Santin (now at the University of the Basque Country) describe the molecular mechanism by which a specific long noncoding RNA regulates pancreatic β-cell inflammation and contributes to the pathogenesis of type 1 diabetes.


Mechanobiology: what makes bacterial pathogens so stiff?
14/04/2020

In a study published in Nature Communications, the teams of Yves Dufrêne and Jean-François Collet (WELBIO investigators) at the UCLouvain have identified the key roles of the lipoprotein Lpp in defining the E. coli cell envelope mechanics, using state-of-the-art nanoimaging techniques combined with genetic manipulation. The results show promise for the design of innovative antibacterial drugs.


European Research Council : new ERC grant for Pr. Cédric Blanpain
31/03/2020

For the third time, Pr. Cédric Blanpain – WELBIO investigator at the Université libre de Bruxelles - has obtained a grant from the European Research Council (ERC). This new project called “TrackingTumorStates” aims to define at the single cell resolution, the mechanisms regulating tumor transition states, responsible for tumor growth, differentiation, invasion, metastasis and resistance to therapy.


RNF113A protein as a new target for the treatment of lung tumours
12/03/2020

Lung cancer remains very challenging to treat, at least because of intrinsic or acquired resistance of lung cancer cells to some targeted therapies. Combinatory approches are needed to circumvent both types of resistance and new therapeutic targets are consequently needed. A study by Prof. Alain Chariot (WELBIO investigator at the GIGA, Liège) and his team consisted in defining the RNF113A protein as a new target for the treatment of lung tumours. This study has been published in Nature Communications.



Last update : 21/1/2015 - Vie privée - Printable version -  © 2020 WELBIO

Home Login